Clovis Breaks Into Europe With EMA Validation

Health and Healthcare

Published: July 5, 2018 8:55 am

Last Updated: January 11, 2020 9:28 pm

Clovis Oncology Inc. (NASDAQ: CLVS) shares saw a bump early on Thursday after the company announced that the European Medicines Agency (EMA) has validated its application for a Type 2 variation to the marketing authorization for Rubraca (rucaparib). This validation confirms the submission is complete and begins the EMA’s centralized review process.

This application of Rubraca includes the maintenance treatment of adult patients with recurrent epithelial ovarian, fallopian tube or primary peritoneal cancer who are in a complete or partial response to platinum-based chemotherapy.

This submission is based on the positive results from the Phase 3 ARIEL3 study, which evaluated rucaparib in the ovarian cancer maintenance treatment. Ultimately, ARIEL3 successfully achieved its primary endpoints, extending investigator assessed progression-free survival versus placebo in all patients treated.

Based on the timing of this submission, the company anticipates an opinion from the Committee for Medicinal Products for Human Use by end of 2018.

Patrick J. Mahaffy, CEO and president of Clovis, commented:

We are very pleased to receive validation of the variation to the Rubraca marketing authorization by the EMA, which brings us a step forward in making rucaparib available to more women with recurrent ovarian cancer in Europe.

Shares of Clovis closed Tuesday at $47.40, with a consensus analyst price target of $75.29 and a 52-week trading range of $41.31 to $99.45. Following the announcement, the stock was up about 1.3% at $48.00 in early trading indications Thursday.

ALSO READ: Merrill Lynch Issues Top 8 US Stock Ideas for Q3 2018

Take Charge of Your Retirement In Just A Few Minutes (Sponsor)

Retirement planning doesn’t have to feel overwhelming. The key is finding expert guidance—and SmartAsset’s simple quiz makes it easier than ever for you to connect with a vetted financial advisor.

Here’s how it works:

Answer a Few Simple Questions. Tell us a bit about your goals and preferences—it only takes a few minutes!
Get Matched with Vetted Advisors Our smart tool matches you with up to three pre-screened, vetted advisors who serve your area and are held to a fiduciary standard to act in your best interests. Click here to begin
Choose Your Fit Review their profiles, schedule an introductory call (or meet in person), and select the advisor who feel is right for you.

Why wait? Start building the retirement you’ve always dreamed of. Click here to get started today!